Objective
to evaluate the efficacy of dapagliflozin (10 mg once daily) as compared to standard care alone in patients undergoing TAVI
Study
multicentre randomised trial in Spain
Population
patients with aortic stenosis undergoing TAVI who had history of heart failure and at least one of the following: renal insufficiency, diabetes or left ventricular systolic dysfunction
Endpoints
composite of any-cause death or worsening heart failure at 1 year
Conclusion
Among patients undergoing TAVI for aortic stenosis, dapagliflozin significantly reduced all-cause death or the worsening of heart failure when compared with standard care alone.
Raposeiras-Roubin et al. N Engl J Med. 2025 Mar 29.